The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05868369
Collaborator
(none)
70
2
2
3
35
11.6

Study Details

Study Description

Brief Summary

  1. The purpose of the research is to assess the efficacy of postoperative immersive virtual reality (iVR) compared to a standard multimodal pain regimen including opioids and a local block on acute postoperative pain management following hip arthroscopy

  2. The primary research procedures are medical record review for demographic information, head-mounted immersive virtual reality experience in PACU, and pre-operative and post-operative surveys

  3. The study will enroll adult patients of all ages undergoing elective hip arthroscopy procedures for any diagnosis

Condition or Disease Intervention/Treatment Phase
  • Device: iVR Group
  • Drug: Standard pain management regimen
N/A

Detailed Description

The overall purpose of this prospective matched cohort investigation is to assess the efficacy of postoperative iVR compared to a standard multimodal pain regimen including opioids, on acute postoperative pain management following hip arthroscopy. The goal is to determine whether iVR in the immediate post-operative ambulatory setting would have any effect on subjective pain, anxiety, and nausea scores or on patients' opioid consumption. The primary objective of this study is to evaluate the effects of administering a head-mounted immersive virtual reality (iVR) experience to control postoperative pain and nausea in patients undergoing hip arthroscopy. The secondary objective of this study is to evaluate the effectiveness of specific iVR modules in pain perception and decreasing overall opioid use for post-operative pain control. We will prospectively compare a cohort of primary hip arthroscopy patients who receive postoperative iVR therapy in addition to the standard multimodal pain regimen (including a preoperative local field block) with a matched cohort of hip arthroscopy patients who receive only the standard regimen (including field block) in the acute postoperative ambulatory setting. On the day of surgery, the iVR group will receive a 30-minute sessions or "dose" of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay in addition to the standard postoperative pain protocol (including a pre-operative local field block). The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes. Both groups will receive the standard postoperative pain protocol on an as needed basis.

The duration of the study is three weeks (pre-operative visit, operative day, and first post-operative visit).

Patients will be screened and enrolled at their pre-operative visit. Included patients will be consented and will fill out the pre-operative questionnaires in order to provide baseline data. They will be randomized into the control group or the iVR therapy group. On the day of surgery, they will undergo their local field block by their anesthesiologist pre-operatively, undergo their hip arthroscopy procedure as indicated by their surgeon, and undergo their VR therapy in PACU as described above. They will be asked for their pain scores when leaving PACU, and their opioid medication usage during PACU will be recorded. Post-operative questionnaires will also be completed prior to discharge from PACU and at the first post-op visit.

The study involves participation at a single timepoint only. The study procedures to be done are listed below: Virtual Reality Therapy in PACU performed once as described above.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effectiveness of Immersive Virtual Reality as a Pain Control Modality After Hip Arthroscopy
Anticipated Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Aug 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Standard regimen +iVR Group

postoperative iVR therapy in addition to the standard multimodal pain regimen (including a preoperative local field block

Device: iVR Group
On the day of surgery, the iVR group will receive a 30-minute sessions or "dose" of iVR therapy in the ambulatory post-anesthesia care unit (PACU) during their stay. The three distraction-based or skills-based iVR modules will consist of either 1) Mindful Escape; 2) Empowered Breathing; or 3) Relaxation videos. The iVR group will be sub-randomized into receiving only one of the three types of modules. The modules will start approximately 30 minutes upon arriving in PACU and will last approximately 30 minutes.

Drug: Standard pain management regimen
In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).

Active Comparator: Standard regimen

hip arthroscopy patients who receive only the standard regimen (including field block) in the acute postoperative ambulatory setting

Drug: Standard pain management regimen
In the ambulatory post-anesthesia care unit (PACU) during their stay with have standard postoperative pain protocol (including a pre-operative local field block).

Outcome Measures

Primary Outcome Measures

  1. Pain visual analog scale (VAS) [one time at Day 1 post operative]

    subjects rate their pain from 0-10, 0 being the least and 10 being the worst.

Secondary Outcome Measures

  1. Anxiety PACU questionnaire [one time Day 1 of surgery post-op]

    On a scale 1-9 1 being the least and 9 being the worst

  2. Nausea PACU Questionnaire [one time Day 1 of surgery post-op]

    On a scale none, slight, moderate and sever.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients 18 years of age or older with hip pathology

  • Failed non-operative treatment of hip pathology

  • Undergoing primary, elective and isolated hip arthroscopy for their hip pathology

  • Complete pre-operative and post-operative questionnaires

Exclusion Criteria:
  • Minors (17 years of age and younger)

  • Traumatic injuries undergoing emergent surgery

  • Undergoing revision hip arthroscopic surgery

  • Do not complete pre-operative and post-operative questionnaires

  • Patients not able to undergo elective surgery

  • Pregnant women

  • Prisoners

  • Patients with conditions that interfere with VR usage including: history of seizure or epilepsy, facial injury precluding safe placement of headset, visual impairment impacting ability to visualize VR images, hearing impairment impacting ability to follow audio instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kerlan Jobe Los Angeles California United States 90045
2 Kerlan Jobe Los Angeles California United States 90045

Sponsors and Collaborators

  • Cedars-Sinai Medical Center

Investigators

  • Study Director: Karen Ladnier, MS, Cedar -Sinai Kerlan jobe orthopedic institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael Banffy, MD, Principal Investigator, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT05868369
Other Study ID Numbers:
  • STUDY00002535
First Posted:
May 22, 2023
Last Update Posted:
May 22, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Michael Banffy, MD, Principal Investigator, Cedars-Sinai Medical Center

Study Results

No Results Posted as of May 22, 2023